Lindblad E B, Elhay M J, Silva R, Appelberg R, Andersen P
The TB Research Unit, Statens Seruminstitut, Copenhagen S., Denmark.
Infect Immun. 1997 Feb;65(2):623-9. doi: 10.1128/iai.65.2.623-629.1997.
Mice were immunized with experimental subunit vaccines based on secreted antigens from Mycobacterium tuberculosis in a series of adjuvants, comprising incomplete Freund's adjuvant (IFA), dimethyl dioctadecyl ammoniumbromide (DDA), RIBI adjuvant, Quil-A saponin, and aluminum hydroxide. Immune responses induced by these vaccines were characterized by in vitro culture of primed cells, PCR analysis for cytokine mRNA, detection of specific immunoglobulin G isotypes induced, and monitoring of protective immunity to tuberculosis (TB). The study demonstrated marked differences in the immune responses induced by the different adjuvants and identified both IFA and DDA as efficient adjuvants for a TB subunit vaccine. Aluminum hydroxide, on the other hand, induced a Th2 response which increased the susceptibility of the animals to a subsequent TB challenge. DDA was further coadjuvanted with either the Th1-stimulating polymer poly(I-C) or the cytokines gamma interferon, interleukin 2 (IL-2), and IL-12. The addition of IL-12 was found to amplify a Th1 response in a dose-dependent manner and promoted a protective immune response against a virulent challenge. However, if the initial priming in the presence of IL-12 was followed by two booster injections of vaccine without IL-12, no improvement in long-term efficacy was found. This demonstrates the efficacy of DDA to promote an efficient immune response and suggests that IL-12 may accelerate this development, but not change the final outcome of a full vaccination regime.
将小鼠用基于结核分枝杆菌分泌抗原的实验性亚单位疫苗在一系列佐剂中进行免疫,这些佐剂包括不完全弗氏佐剂(IFA)、二甲基二十八烷基溴化铵(DDA)、RIBI佐剂、Quil-A皂苷和氢氧化铝。这些疫苗诱导的免疫反应通过致敏细胞的体外培养、细胞因子mRNA的PCR分析、诱导的特异性免疫球蛋白G同种型的检测以及对结核病(TB)保护性免疫的监测来表征。该研究证明了不同佐剂诱导的免疫反应存在显著差异,并确定IFA和DDA都是结核亚单位疫苗的有效佐剂。另一方面,氢氧化铝诱导了Th2反应,增加了动物对随后结核攻击的易感性。DDA进一步与Th1刺激聚合物聚肌胞苷酸(poly(I-C))或细胞因子γ干扰素、白细胞介素2(IL-2)和IL-12共同佐剂。发现添加IL-12以剂量依赖方式放大Th1反应,并促进针对强毒攻击的保护性免疫反应。然而,如果在存在IL-12的情况下进行初始致敏,随后进行两次不含IL-12的疫苗加强注射,则未发现长期疗效有改善。这证明了DDA促进有效免疫反应的功效,并表明IL-12可能加速这一过程,但不会改变完整疫苗接种方案的最终结果。